Global Molecular Infectious Disease Testing Market Size study & Forecast, by Product (Instruments, Reagents), Technology (Mass Spectrometry, PCR, In Situ Hybridization), Application, End-use and Regional Forecasts 2025-2035

The Global Molecular Infectious Disease Testing Market, valued at approximately USD 16.2 billion in 2024, is projected to expand at a steady CAGR of around 3.40% during the forecast period from 2025 to 2035, ultimately reaching about USD 23.40 billion by the end of the period. Molecular infectious disease testing, a cornerstone of modern diagnostics, has transformed the way clinicians identify, monitor, and manage infectious agents with unmatched precision and speed. Leveraging advanced molecular technologies, these tests detect specific genetic material from pathogens, enabling early detection and targeted treatment plans. The market’s growth trajectory is being fueled by the persistent burden of infectious diseases, the heightened global awareness following recent pandemic events, and the increasing integration of molecular diagnostics in routine healthcare settings. Additionally, rapid advancements in assay design, automated workflows, and point-of-care molecular systems are enhancing operational efficiency and reducing turnaround times for critical diagnoses.

An upsurge in demand for reliable and high-throughput testing solutions is further catalyzing market expansion, as healthcare providers aim to curb outbreaks and improve patient outcomes. The adoption of molecular diagnostics in decentralized healthcare environments—ranging from outpatient clinics to home-based testing—has opened new revenue streams for industry stakeholders. According to industry insights, the continued prevalence of healthcare-associated infections and emerging antimicrobial resistance patterns has compelled laboratories to adopt molecular platforms capable of multiplex detection and antimicrobial resistance profiling. Moreover, the integration of artificial intelligence and big data analytics into molecular testing workflows is revolutionizing result interpretation, paving the way for predictive epidemiology and more efficient public health interventions. However, cost-intensive instrumentation, the need for skilled laboratory personnel, and disparities in diagnostic infrastructure across emerging economies continue to present challenges to market penetration.

From a regional perspective, North America held the dominant share of the market in 2024, benefiting from robust healthcare infrastructure, widespread adoption of cutting-edge diagnostic tools, and strong funding for infectious disease surveillance. The United States, with its well-established network of clinical laboratories and public health agencies, remains a key driver of innovation and adoption in this sector. Europe follows closely, propelled by rising investments in genomic medicine, regulatory support for rapid diagnostic deployment, and heightened vigilance against cross-border disease transmission. The Asia Pacific region is anticipated to witness the fastest growth through 2035, fueled by a surging patient base, government-led healthcare modernization programs, and increased private sector investment in diagnostic capabilities. Countries like China and India are rapidly scaling up their molecular testing capacities to meet the demands of urbanization, globalization, and shifting disease epidemiology. Meanwhile, Latin America and the Middle East & Africa are gradually strengthening their diagnostic ecosystems through collaborative initiatives and donor-funded projects aimed at bolstering infectious disease control programs.

Major market player included in this report are:
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Becton, Dickinson and Company
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Qiagen N.V.
• Hologic, Inc.
• bioMérieux SA
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers AG
• GenMark Diagnostics, Inc.
• Agilent Technologies, Inc.
• Luminex Corporation
• Cepheid (a Danaher Company)

Global Molecular Infectious Disease Testing Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period - 2025-2035
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segments of the market are explained below:

By Product:
• Instruments
• Reagents

By Technology:
• Mass Spectrometry
• PCR
• In Situ Hybridization

By Application:
• [Application-specific segmentation to be detailed based on market data]

By End-use:
• [End-use-specific segmentation to be detailed based on market data]

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more